These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow CW; Obeso JA; Stocchi F Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589 [TBL] [Abstract][Full Text] [Related]
31. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients. Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647 [TBL] [Abstract][Full Text] [Related]
32. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)]. Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935 [TBL] [Abstract][Full Text] [Related]
33. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lang AE; Obeso JA Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546 [TBL] [Abstract][Full Text] [Related]
34. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease. Di Luca DG; Reyes NGD; Fox SH Drugs; 2022 Jul; 82(10):1027-1053. PubMed ID: 35841520 [TBL] [Abstract][Full Text] [Related]
35. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease]. Antonini A; Jost WH Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620 [TBL] [Abstract][Full Text] [Related]
36. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
37. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]. Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100 [TBL] [Abstract][Full Text] [Related]
38. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. You H; Mariani LL; Mangone G; Le Febvre de Nailly D; Charbonnier-Beaupel F; Corvol JC Cell Tissue Res; 2018 Jul; 373(1):111-135. PubMed ID: 29516217 [TBL] [Abstract][Full Text] [Related]
39. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Wright BA; Waters CH Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008 [TBL] [Abstract][Full Text] [Related]
40. Safinamide for the treatment of Parkinson's disease. Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]